



**SPECIALITY MEDICINE AND TECHNOLOGY BENEFIT (SMTB)**

In addition to Prescribed Minimum Benefit entitlement, a member on the LA Comprehensive Option shall be entitled, upon meeting the Scheme’s clinical entry criteria, to benefits in terms of Annexure B of these Rules.

Included in the member’s SMTB is cover for the following categories, as defined in the table below:

1. High-cost chronic medicine based on the Scheme’s defined list of medicine and /or,
2. Surgical procedures based on the Scheme’s defined list of procedures.

**Basis**

The calculation of the amount payable by the Scheme in respect of these benefits may be based on:

- The billing guidelines applicable and / or contracted arrangements entered by the Scheme with the healthcare provider concerned for surgical procedures, and
- The applicable tariff (or a percentage of such tariff) in respect of high-cost chronic medicine.

**Scheme’s liability**

The Scheme’s liability in respect of the SMTB shall be limited in each financial year to between 80% and 100% of the LA Health Rate, or up to a maximum of the reference price for preferentially priced medicine, depending on the specific treatment outlined in the table below, and up the specific R value limit as stipulated in the relevant section of Annexure B1, subject to the beneficiary having met the Scheme’s required clinical criteria.

The Scheme’s liability in respect of such treatments will also be subject to what is stated in this Annexure.

The basis of cover for a defined list of treatment include:

<b>Treatment</b>	<b>Condition</b>	<b>Basis of cover</b>
Revellex®	Ankylosing Spondylitis Psoriatic arthritis	80% of the LA Health Rate
Remsima® Remifix®	Rheumatoid Arthritis Chron's disease Ulcerative colitis	Up to a maximum of the reference price of the preferentially priced equivalent
MabThera® Blitzima® Ristova®	Rheumatoid Arthritis	Up to a maximum of the reference price of the preferentially priced equivalent
Enbrel®	Ankylosing Spondylitis Psoriatic arthritis	80% of the LA Health Rate
Erelzi®	Rheumatoid Arthritis	Up to a maximum of the reference price of the preferentially priced equivalent
Actemra® Orencia®	Rheumatoid Arthritis	Up to a maximum of the reference price of the preferentially priced equivalent
Cosentyx®	Ankylosing Spondylitis Psoriatic arthritis	80% of the LA Health Rate
Humira® Amgevita®	Ankylosing spondylitis Psoriatic arthritis Rheumatoid arthritis Crohn's disease Ulcerative colitis	Up to a maximum of the reference price of the preferentially priced equivalent
Simponi®	Ankylosing spondylitis Psoriatic arthritis	80% of the LA Health Rate
	Rheumatoid arthritis Ulcerative colitis	Up to a maximum of the reference price of the preferentially priced equivalent
Stelara®	Psoriatic arthritis Crohn's disease Ulcerative colitis	80% of the LA Health Rate Up to a maximum of the reference price of the preferentially priced equivalent

2023/11/08

REGISTRAR OF MEDICAL SCHEMES

Entyvio®	Crohn's disease Ulcerative colitis	Up to a maximum of the reference price of the preferentially priced equivalent
Copellor®	Psoriatic arthritis	80% of the LA Health Rate
Sensipar®	Chronic renal disease	100% of the LA Health Rate
Forteo® Prolia®	Osteoporosis	80% of the LA Health Rate
Esbriet®	Pulmonary fibrosis	80% of the LA Health Rate
<b>Other high-cost treatment and surgical procedures</b>		
Pegasys® PegIntron®	Hepatitis C	80% of the LA Health Rate
Ozurdex®	Retinal vein occlusion Diabetic macular oedema	80% of the LA Health Rate
Bariatric surgery	Obesity	80% of the LA Health Rate
Balloon sinuplasty	Chronic sinusitis	80% of the LA Health Rate
HALO oesophageal ablation system	Barrett's oesophagus with dysplasia	100% of the LA Health Rate

### Funding of claims

The Scheme shall only be required to fund medical technologies and treatments not previously funded, or existing treatments for new clinical indications, and/or unregistered medicines from the Major Medical Benefit if such medical treatments meet the Scheme's protocols, where they exist, which shall be developed based on evidence-based medicine and cost-effectiveness criteria.